Labor or Delivery
There are no studies on the effects of FELDENE during labor or delivery. In animal studies, NSAIDS, including Rexicam inhibit prostaglandin synthesis, cause delayed parturition, and increase the incidence of stillbirth.
Pregnant rats administered Rexicam at 2, 5, or 10 mg/kg/day during the period of organogenesis (Gestation Days 6 to 15) demonstrated increased post-implantation losses with 5 and 10 mg/kg/day of Rexicam (equivalent to 2 and 5 times the maximum recommended human dose , of 20 mg respectively, based on a mg/m 2 body surface area ). There were no drug-related developmental abnormalities noted in offspring. Gastrointestinal tract toxicity was increased in pregnant rats in the last trimester of pregnancy compared to non-pregnant rats or rats in earlier trimesters of pregnancy. Pregnant rabbits administered Rexicam at 2, 5, or 10 mg/kg/day during the period of organogenesis (Gestation Days 7 to 18) demonstrated no drug-related developmental abnormalities in offspring (up to 10 times the MRHD based on a mg/m 2 BSA).
In a pre- and post-natal development study in which pregnant rats were administered Rexicam at 2, 5, or 10 mg/kg/day on Gestation Day 15 through delivery and weaning of offspring, reduced weight gain and death were observed in dams at 10 mg/kg/day (5 times the MRHD based on a mg/m 2 BSA) starting on Gestation Day 20. Treated dams revealed peritonitis, adhesions, gastric bleeding, hemorrhagic enteritis and dead fetuses in utero. Parturition was delayed and there was an increased incidence of stillbirth in all Rexicam-treated groups (at doses equivalent to the MRHD). Postnatal development could not be reliably assessed due to the absence of maternal care secondary to severe maternal toxicity.
What is Rexicam?
Rexicam is a nonsteroidal anti-inflammatory drug (NSAID).
Rexicam is used to treat pain or inflammation caused by osteoarthritis or rheumatoid arthritis.
Rexicam may also be used for purposes not listed in this medication guide.
Rexicam was not mutagenic in an Ames bacterial reverse mutation assay, or in a dominant lethal mutation assay in mice, and was not clastogenic in an in vivo chromosome aberration assay in mice.
Rexicam is a member of the oxicam family of NSAIDs. In vitro data suggest that Rexicam is COX-2 selective in dogs. 14,104 However, in vivo data are not available to confirm these results. Rexicam has an elimination half-life of approximately 40 hours in the dog. 105 Rexicam has been used as an antineoplastic agent to treat transitional cell neoplasia in dogs. Although antineoplastic activity has been linked to COX-2 inhibitory activity, other factors may also play a role in the antineoplastic activity of Rexicam. Based on clinical response and this long elimination half-life, once daily or once every other day dosing has been successfully used in the dog. Rexicam has been administered at a dose of 0.3 mg/kg orally once daily for many months for the treatment of canine transitional cell neoplasia. At this dose, approximately 18% of patients demonstrated adverse GI signs. 106 Gastroendoscopic evaluation of healthy dogs given Rexicam at a dose of 0.3 mg/kg orally once daily for 28 days failed to demonstrate a difference in gastroduodenal lesion development between treated and control dogs. 107 Additional data are needed before sweeping recommendations on use in pain management can be made. Pharmacokinetic data are available in cats given single and multiple doses of Rexicam. However, until efficacy and long-term safety studies are completed in cats, Rexicam cannot be recommended. 108,109
¿Qué sucedería en una sobredosis?
Busque atención medica de emergencia si sospecha que ha usado demasiado de esta medicina. Los síntomas de una sobredosis de Rexicam puede incluir náusea, vómito, dolor de estómago, heces fecales negras o con sangre, o tos con sangre.
References updated: 20 January 2014
153,000 prescriptions of diclofenac,
65,000 of Rexicam,
138,000 of naproxen: 6 cases attributed to naproxen , 3 to diclofenac , none to Rexicam ).
Getting the most from your treatment
- Try to avoid the gel coming into contact with your eyes, and do not apply it to any broken or irritated areas of your skin. If this does happen by accident, wash it off with warm water as soon as possible.
- It is important that you don't cover any area of skin that has been treated with the gel with any dressings or bandages. This is because more Rexicam may be absorbed by your skin than is intended, and this could lead to unwanted effects.
- Rexicam could cause your skin to become more sensitive to sunlight than normal. Do not use sunbeds, and protect any treated areas from strong sunlight until you know how your skin reacts.
How to store Rexicam
Rexicam is a member of the oxicam family of NSAIDs. In vitro data suggest that Rexicam is COX-2 selective in dogs. However, in vivo data are not available to confirm these results. Rexicam has an elimination half-life of approximately 40 hours in the dog and 12 hours in the cat. Rexicam has long been used as an antineoplastic agent to treat transitional cell carcinoma, and it is now also being used as an adjunct therapy in other chemotherapy regimens to treat squamous cell carcinoma and mammary carcinoma. Although antineoplastic activity has been linked to COX-2 inhibitory activity, other factors may also play a role in Rexicam's antineoplastic activity. Based on clinical response and the long elimination half-life, once-daily or once-every-other-day administration has been successfully used in the dog. Rexicam has been administered at a dose of 0.3 mg/kg orally once daily for many months for the treatment of canine transitional cell carcinoma. Approximately 18% of the dogs demonstrated adverse GI signs. Clinical reports are vague regarding exact adverse events, but these events seem to be limited. Gastroendoscopic evaluation of healthy dogs given Rexicam at a dose of 0.3 mg/kg orally once daily for 28 days failed to demonstrate a difference in gastroduodenal lesion development between treated and control dogs. Additional data are needed before sweeping recommendations on use in pain management can be made.
Rexicam is a non-steroidal anti-inflammatory drug of the ‘oxicam’ class used to relieve the symptoms of rheumatoid and osteoarthritis. It has also been used in small animal veterinary medicine to treat certain neoplasia expressing cyclooxygenase (COX) receptors, such as bladder, colon and prostate cancers. 68 There are few reports of its use in horses, but it would seem to be potentially valuable in the management of bladder and urethral tumours. There are reports of its adjunctive value in supporting treatment of some ocular and mucocutaneous carcinoma cases at 150 mg/kg per os q 24 h × 10, then q 48 h for several months. 69
The possible side-effects are not established in horses.
Serious side effects
Call your doctor right away if you have serious side effects. Call 911 if your symptoms feel life-threatening or if you think you’re having a medical emergency. Serious side effects and their symptoms can include the following:
- Allergic reaction. Symptoms can include:
- skin rash
- itching or hives
- swelling of your face, lips, or tongue
- chest pain
- shortness of breath
- weakness on one side of your body
- slurred speech
Disclaimer: Our goal is to provide you with the most relevant and current information. However, because drugs affect each person differently, we cannot guarantee that this information includes all possible side effects. This information is not a substitute for medical advice. Always discuss possible side effects with a healthcare provider who knows your medical history.
Rexicam oral capsule can interact with other medications, vitamins, or herbs you may be taking. An interaction is when a substance changes the way a drug works. This can be harmful or prevent the drug from working well.
To help avoid interactions, your doctor should manage all of your medications carefully. Be sure to tell your doctor about all medications, vitamins, or herbs you’re taking. To find out how this drug might interact with something else you’re taking, talk to your doctor or pharmacist.
Examples of drugs that can cause interactions with Rexicam are listed below.
Anemia has occurred in NSAID-treated patients. This may be due to occult or gross blood loss, fluid retention, or an incompletely described effect on erythropoiesis. If a patient treated with Rexicam has any signs or symptoms of anemia, monitor hemoglobin or hematocrit.
NSA > .
Rexicam has not been investigated in pediatric patients. The safety and effectiveness of Rexicam have not been established.
What Other Drugs Interact with Rexicam ?
If your doctor has directed you to use this medication, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, health care provider or pharmacist first.
Rexicam has no known severe interactions with other drugs.
Serious interactions of Rexicam include:
Rexicam has moderate interactions with 237 different drugs.
Rexicam has mild interactions with at least 115 different drugs.
This information does not contain all possible interactions or adverse effects. Therefore, before using this product, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you, and share this information with your doctor and pharmacist. Check with your health care professional or doctor for additional medical advice, or if you have health questions, concerns or for more information about this medicine.
Rexicam disease interactions
There are 12 disease interactions with Rexicam which include:
Symptoms following acute NSA > .
Manage patients with symptomatic and supportive care following an NSAID overdose. There are no specific antidotes. Consider emesis and/or activated charcoal (60 grams to100 grams in adults, 1 gram to 2 grams per kg of body weight in pediatric patients) and/or osmotic cathartic in symptomatic patients seen within four hours of ingestion or in patients with a large overdosage (5 times to 10 times the recommended dosage).
The long plasma half-life of Rexicam should be considered when treating an overdose with Rexicam. Forced diuresis, alkalinization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding.
For additional information about overdosage treatment contact a poison control center (1-800-222-1222).
Exacerbation of Asthma Related to Aspirin Sensitivity
A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps; severe, potentially fatal bronchospasm; and/or intolerance to aspirin and other NSA > . When Rexicam is used in patients with preexisting asthma (without known aspirin sensitivity), monitor patients for changes in the signs and symptoms of asthma.
DiureticsClinical Impact:Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis.Intervention:During concomitant use of FELDENE with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects .DigoxinClinical Impact:The concomitant use of Rexicam with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.Intervention:During concomitant use of FELDENE and digoxin, monitor serum digoxin levels.LithiumClinical Impact:NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance. The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%. This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis.Intervention:During concomitant use of FELDENE and lithium, monitor patients for signs of lithium toxicity.MethotrexateClinical Impact:Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction).Intervention:During concomitant use of FELDENE and methotrexate, monitor patients for methotrexate toxicity.CyclosporineClinical Impact:Concomitant use of FELDENE and cyclosporine may increase cyclosporine's nephrotoxicity.Intervention:During concomitant use of FELDENE and cyclosporine, monitor patients for signs of worsening renal function.NSAIDs and SalicylatesClinical Impact:Concomitant use of Rexicam with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy .Intervention:The concomitant use of Rexicam with other NSAIDs or salicylates is not recommended.PemetrexedClinical Impact:Concomitant use of FELDENE and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information).Intervention:During concomitant use of FELDENE and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity. NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration.Highly Protein Bound DrugsClinical Impact:FELDENE is highly protein bound and, therefore, might be expected to displace other protein bound drugs.Intervention:Physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on other highly protein bound drugs.CorticosteroidsClinical Impact:Concomitant use of corticosteroids with FELDENE may increase the risk of GI ulceration or bleeding.Intervention:Monitor patients with concomitant use of FELDENE with corticosteroids for signs of bleeding .